Treatment of a patient with congenital analbuminemia with atorvastatin and albumin infusion

• 作 者: Maria Del Ben Francesco Angelico Lorenzo Loffredo Francesco Violi
• 机 构: Clinica Medica I, Sapienza University, 00161 Rome, Italy,
• 出 处: World Journal of Clinical Cases
• 发表日期: 2013年01期
• 关键词: congenital infusion albumin cardiovascular recessive hypotension cholesterol app

Congenital analbuminemia is a rare autosomic recessive inherited disorder characterized by low plasma albumin and hypercholesterolemia, which may increase cardiovascular risk. Patients are essentially asymptomatic, apart from ease of fatigue, minimal ankle oedema and hypotension. There is no accepted strategy for safely treating both hypercholesterolemia and analbuminemia in order to eventually decrease the atherosclerotic risk. We report a case of congenital analbuminemia(1.0 g/dL) in a 38-year-old male with hypercholesterolemia(range: 406-475 mg/dL) and severe arterial dysfunction [no brachial artery flow-mediated dilation(FMD)]. Long-term, cholesterol-lowering treatment with atorvastatin was associated with the appearance of peripheral edema. Twomonths of infusion with albumin improved FMD(7%) and reduced serum cholesterol(273 mg/dL), supporting the hypothesis of a compensatory role of hypercholesterolemia. Statin treatment, together with periodical albumin infusions, may contribute to the safe reduction of cardiovascular risk.

Congenital analbuminemia is a rare autosomic recessive inherited disorder characterized by low plasma albumin and hypercholesterolemia, which may increase cardiovascular risk. Patients are essentially asymptomatic, apart from ease of fatigue, minimal ankle oedema and hypotension. There is no accepted strategy for treating both hypercholesterolemia and analbuminemia in order to ultimately decrease the atherosclerotic risk. We report a case of congenital analbuminemia (1.0 g / dL) in a 38-year-old male with hypercholesterolemia (range: 406-475 mg / dL) and severe arterial dysfunction [no Long-term, cholesterol-lowering treatment with atorvastatin was associated with the appearance of peripheral edema. Twomonths of infusion with albumin-improved FMD (7%) and reduced serum cholesterol (273 mg / dL ), supporting the hypothesis of a compensatory role of hypercholesterolemia. Statin treatment, together with periodical albumin infusions, may contribute to the safe reduction of cardiovascular risk.